drugset
drugset / Trial / NCT07142837

Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors

NCT07142837 ↗

Phase 1/2 Not yet recruiting 153 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd
RandomizedSequentialOpen-labelTreatment

Summary

This is a multicenter, open-label phase I/II study for participants with advanced solid tumors who have failed prior immune checkpoint inhibitor therapies.

Timeline

Start
2025-09
Primary completion
2027-10
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Gecacitinib Unknown 100 mg Oral
Subject ZG005 Unknown 20 mg/kg Intravenous

Indications

neoplasm